Will Nestle (NSRGY) Stock Be Affected By $1.4 Billion Skin Care Deal?

NEW YORK (TheStreet) -- Looking to extend its skin care unit, Nestle (NSRGY) will pay $1.4 billion in cash for the right to sell products made by Valeant Pharmaceuticals (VRX), Bloomberg reported.

The Switzerland-based holding company for the Nestle Group is looking to purchase the facial aesthetic treatments Restylane, Perlane, and Emervel to sell in the U.S. and Canada. The company already sells those products outside of North America.

Nestle is looking to build up a strong skin-care unit as its main food business struggles, Bloomberg noted.

Must ReadWarren Buffett's 25 Favorite Stocks 

NSRGY Chart NSRGY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Nestle Goes Vegan with Sweet Earth Purchase

Nestle Shares Will Rise If CEO Is Bold, Goldman Sachs Predicts

Cocoa Prices Are Plunging. Here's What It Means to Hershey

These Are the Top Leadership Traits the Next CEO of Uber Must Have